NCT02682498View on ClinicalTrials.gov

Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj

PHASE4CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

August 31, 2015

Conditions
Arthroplasty, Replacement, Knee
Interventions
DRUG

(Bupivacaine Liposome Injectable Suspension)

Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.

DRUG

Standard Preparation

A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.

Trial Locations (1)

92868

UC Irvine Medical Center, Orange

All Listed Sponsors
lead

University of California, Irvine

OTHER

NCT02682498 - Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj | Biotech Hunter | Biotech Hunter